[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.239.150.57. Please contact the publisher to request reinstatement.

Blinatumomab for B-cell ALL Relapse, IVIG for MIS-C, Review of Irritable Bowel Syndrome, and more

JAMA
March 2, 2021 Audio Editors' Summary 10 min 38 sec
<title>Blinatumomab for B-cell ALL Relapse, IVIG for MIS-C, Review of Irritable Bowel Syndrome, and more</title>
Backward 15 Play Pause Forward 15
1x
0:00 / 0:00
Download MP3

Editor's Summary by Mary McDermott, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the March 2, 2021 issue
Subscribe

Subscribe on your favorite podcast source to receive future episodes of this podcast.
Learn more about this JAMA Network podcast here

Related Articles

  1. Audio Highlights

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Privacy Policy|Terms of Use
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue